Brain region-specific decrease in the activity and expression of protein kinase a in the frontal cortex of regressive autism

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Ji, Lina ^a,b   Chauhan, Ved ^a   Flory, Michael J ^a   Chauhan, Abha ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; PROTEIN KINASE C ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PRKAA1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; AUTISM; AUTOPSY; CEREBELLUM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; OCCIPITAL CORTEX; PARIETAL CORTEX; PRESCHOOL CHILD; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGRESSIVE AUTISM; REMISSION; SCHOOL CHILD; SIGNAL TRANSDUCTION; TEMPORAL CORTEX; ANTIBODY SPECIFICITY; BEHAVIOR; CASE CONTROL STUDY; DONOR; ENZYME ACTIVE SITE; ENZYMOLOGY; FRONTAL LOBE; METABOLISM; PATHOLOGY;

ADOLESCENT; ADULT; AMP-ACTIVATED PROTEIN KINASES; AUTISTIC DISORDER; BEHAVIOR; CASE-CONTROL STUDIES; CATALYTIC DOMAIN; CHILD; CHILD, PRESCHOOL; FEMALE; FRONTAL LOBE; HUMANS; MALE; ORGAN SPECIFICITY; TISSUE DONORS; YOUNG ADULT;

EID: 80052322761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023751     Document Type: Article

References (65)

1. Lord C, Cook EH, Leventhal BL, Amaral DG, (2000) Autism spectrum disorders. Neuron 28: 355-363.
2. Rice C, (2009) Prevalence of autism spectrum disorders- Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ 58: 1-20.
3. Ozonoff S, Williams BJ, Landa R, (2005) Parental report of the early development of children with regressive autism: the delays-plus-regression phenotype. Autism 9: 461-486.
4. Goldberg WA, Osann K, Filipek PA, Laulhere T, Jarvis K, et al. (2003) Language and other regression: assessment and timing. J Autism Dev Disord 33: 607-616.
5. Lord C, Shulman C, DiLavore P, (2004) Regression and word loss in autistic spectrum disorders. J Child Psychol Psychiatry 45: 936-955.
6. Hansen RL, Ozonoff S, Krakowiak P, Angkustsiri K, Jones C, et al. (2008) Regression in autism: prevalence and associated factors in the CHARGE Study. Ambul Pediatr 8: 25-31.
7. Stefanatos GA, (2008) Regression in autistic spectrum disorders. Neuropsychol Rev 18: 305-319.
8. Stefanatos GA, Grover W, Geller E, (1995) Case study: corticosteroid treatment of language regression in pervasive developmental disorder. J Am Acad Child Adolesc Psychiatry 34: 1107-1111.
9. Luyster R, Richler J, Risi S, Hsu WL, Dawson G, et al. (2005) Early regression in social communication in autism spectrum disorders: a CPEA Study. Dev Neuropsychol 27: 311-336.
10. Alcazar A, Fando JL, Azuara C, Galea E, Salinas M, (1986) Protein kinase activities associated with ribosomes of developing rat brain. Identification of eukaryotic initiation factor 2 kinases. Int J Dev Neurosci 4: 525-535.
11. Hamada H, Zhang YL, Kawai A, Li F, Hibino Y, et al. (2003) Development-associated myristoylated alanine-rich C kinase substrate phosphorylation in rat brain. Childs Nerv Syst 19: 152-158.
12. Leonard AS, Hell JW, (1997) Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. J Biol Chem 272: 12107-12115.
13. Turner RS, Raynor RL, Mazzei GJ, Girard PR, Kuo JF, (1984) Developmental studies of phospholipid-sensitive Ca2+-dependent protein kinase and its substrates and of phosphoprotein phosphatases in rat brain. Proc Natl Acad Sci USA 81: 3143-3147.
14. Abel T, Nguven PV, (2008) Regulation of hippocampus-dependent memory by cyclic AMP-dependent protein kinase. Prog Brain Res 169: 97-115.
15. Micheau J, Riedel G, (1999) Protein kinases: which one is the memory molecule? Cell Mol Life Sci 55: 534-548.
16. Nie T, McDonough CB, Huang T, Nguyen PV, Abel T, (2007) Genetic disruption of protein kinase A anchoring reveals a role for compartmentalized kinase signaling in theta-burst long-term potentiation and spatial memory. J Neurosci 27: 10278-10288.
17. Sebeo J, Hsiao K, Bozdagi O, Dumitriu D, Ge Y, et al. (2009) Requirement for protein synthesis at developing synapses. J Neurosci 29: 9778-9793.
18. Nguven PV, Woo NH, (2003) Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein Kinases. Prog Neurobiol 71: 401-437.
19. Karege F, Schwald M, Papadimitriou P, Lachausse C, Cisse M, (2004) The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. J Affect Disord 79: 187-192.
20. Tardito D, Tura GB, Bocchio L, Bignotti S, Pioli R, et al. (2000) Abnormal levels of cAMP-dependent protein kinase regulatory subunits in platelets from schizophrenic patients. Neuropsychopharmacology 23: 216-219.
21. Tardito D, Maina G, Tura GB, Bogetto F, Pioli R, et al. (2001) The cAMP-dependent protein kinase substrate Rap1 in platelets from patients with obsessive compulsive disorder or schizophrenia. Eur Neuropsychopharmacol 11: 221-225.
22. Tardito D, Zanardi R, Racagni G, Manzoni T, Perez J, (2002) The protein kinase A in platelets from patients with panic disorder. Eur Neuropsychopharmacol 12: 483-487.
23. Braun NN, Reutiman TJ, Lee S, Folsom TD, Fatemi SH, (2007) Expression of phosphodiesterase 4 is altered in the brains of subjects with autism. Neuroreport 18: 1841-1844.
24. Blaschke RJ, Monaghan AP, Bock D, Rappold GA, (2000) A novel murine PKA-related protein kinase involved in neuronal differentiation. Genomics 64: 187-194.
25. Tully T, Quinn WG, (1985) Classical conditioning and retention in normal and mutant Drosophila melanogaster. J Comp Physiol A 157: 263-277.
26. Goodwin SF, Del Vecchio M, Velinzon K, Hogel C, Russell SR, et al. (1997) Defective learning in mutants of the Drosophila gene for a regulatory subunit of cAMP-dependent protein kinase. J Neurosci 17: 8817-8827.
27. Li W, Tully T, Kalderon D, (1996) Effects of a conditional Drosophila PKA mutant on olfactory learning and memory. Learn Mem 2: 320-333.
28. Skoulakis EM, Kalderon D, Davis RL, (1993) Preferential expression in mushroom bodies of the catalytic subunit of protein kinase A and its role in learning and memory. Neuron 11: 197-208.
29. Horiuchi J, Yamazaki D, Naganos S, Aigaki T, Saitoe M, (2008) Protein kinase A inhibits a consolidated form of memory in Drosophila. Proc Natl Acad Sci USA 105: 20976-20981.
30. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E, (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 95: 15020-15025.
31. Bach ME, Barad M, Son H, Zhuo M, Lu YF, et al. (1999) Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci USA 96: 5280-5285.
32. Yin JC, Del Vecchio M, Zhou H, Tully T, (1995) CREB as a memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila. Cell 81: 107-115.
33. Perazzona B, Isabel G, Preat T, Davis RL, (2004) The role of cAMP response element-binding protein in Drosophila long-term memory. J Neurosci 24: 8823-8828.
34. Yin JC, Wallach JS, Del Vecchio M, Wilder EL, Zhou H, et al. (1994) Induction of a dominant negative CREB transgene specifically blocks long-term memory in Drosophila. Cell 79: 49-58.
35. Blokland A, Schreiber R, Prickaerts J, (2006) Improving memory: a role for phosphodiesterases. Curr Pharm Des 12: 2511-2523.
36. Rose GM, Hopper A, De Vivo M, Tehim A, (2005) Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 11: 3329-3334.
37. Wachtel H, (1983) Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′, 5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22: 267-272.
38. Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S, et al. (2003) A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA 100: 10518-10522.
39. Rutten K, Lieben C, Smits L, Blokland A, (2007) The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berl) 192: 275-282.
40. Egawa T, Mishima K, Matsumoto Y, Iwasaki K, Iwasaki K, et al. (1997) Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol 75: 275-281.
41. Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, et al. (2005) Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berl) 179: 613-619.
42. Zhang HT, O'Donnell JM, (2000) Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology (Berl) 150: 311-316.
43. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, et al. (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114: 1624-1634.
44. Nagakura A, Niimura M, Takeo S, (2002) Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats. Br J Pharmacol 135: 1783-1793.
45. Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, et al. (1992) A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26: 59-64.
46. McLachlan CS, Chen ML, Lynex CN, Goh DL, Brenner S, et al. (2007) Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease. Arch Neurol 64: 456-457.
47. Parkes JD, Thompson C, Brennan L, Gajraj N, Howcroft B, et al. (1984) Rolipram in Parkinson's disease. Adv Neurol 40: 563-565.
48. Yang L, Calingasan NY, Lorenzo BJ, Beal MF, (2008) Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol 211: 311-314.
49. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, et al. (2007) Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 144: 239-246.
50. Siuciak JA, Chapin DS, McCarthy SA, Martin AN, (2007) Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 192: 415-424.
51. Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M, (1995) Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol 282: 71-76.
52. Sasaki H, Hashimoto K, Maeda Y, Inada T, Kitao Y, et al. (1995) Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci 56: L443-L447.
53. Anderson GM, Horne WC, Chatterjee D, Cohen DJ, (1990) The hyperserotonemia of autism. Ann NY Acad Sci 600: 331-340.
54. Hranilovic D, Novak R, Babic M, Novokmet M, Bujas-Petkovic Z, et al. (2008) Hyperserotonemia in autism: the potential role of 5HT-related gene variants. Coll Antropol 32 (Suppl 1): 75-80.
55. Hranilovic D, Bujas-Petkovic Z, Tomicic M, Bordukalo-Niksic T, Blazevic S, et al. (2009) Hyperserotonemia in autism: activity of 5HT-associated platelet proteins. J Neural Transm 116: 493-501.
56. Foguet M, Hartikka JA, Schmuck K, Lubbert H, (1993) Long-term regulation of serotonergic activity in the rat brain via activation of protein kinase A. EMBO J 12: 903-910.
57. Galter D, Unsicker K, (2000) Brain-derived neurotrophic factor and trkB are essential for cAMP-mediated induction of the serotonergic neuronal phenotype. J Neurosci Res 61: 295-301.
58. Deogracias R, Espliguero G, Iglesias T, Rodriguez-Pena A, (2004) Expression of the neurotrophin receptor trkB is regulated by the cAMP/CREB pathway in neurons. Mol Cell Neurosci 26: 470-480.
59. Hjerrild M, Stensballe A, Jensen ON, Gammeltoft S, Rasmussen TE, (2004) Protein kinase A phosphorylates serine 267 in the homeodomain of engrailed-2 leading to decreased DNA binding. FEBS Lett 568: 55-59.
60. Morgan R, (2006) Engrailed: complexity and economy of a multi-functional transcription factor. FEBS Lett 580: 2531-2533.
61. Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G, et al. (2005) Support for the homeobox transcription factor gene ENGRAILED 2 as an autism spectrum disorder susceptibility locus. Am J Hum Genet 77: 851-868.
62. Cheh MA, Millonig JH, Roselli LM, Ming X, Jacobsen E, et al. (2006) En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder. Brain Res 1116: 166-176.
63. Gharani N, Benayed R, Mancuso V, Brzustowicz LM, Millonig JH, (2004) Association of the homeobox transcription factor, ENGRAILED 2, 3, with autism spectrum disorder. Mol Psychiatry 9: 474-484.
64. Sen B, Singh AS, Sinha S, Chatterjee A, Ahmed S, et al. (2010) Family-based studies indicate association of Engrailed 2 gene with autism in an Indian population. Genes Brain Behav 9: 248-255.
65. Wang L, Jia M, Yue W, Tang F, Qu M, et al. (2008) Association of the ENGRAILED 2 (EN2) gene with autism in Chinese Han population. Am J Med Genet B Neuropsychiatr Genet 147B: 434-438.